Affordable Access

Publisher Website

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.

Authors
Type
Published Article
Journal
The Lancet Oncology
1470-2045
Publisher
Elsevier
Publication Date
Volume
14
Issue
10
Pages
981–988
Identifiers
DOI: 10.1016/S1470-2045(13)70310-3
PMID: 23883922
Source
Medline

Abstract

Our results show that chemotherapy is more effective than erlotinib for second-line treatment for previously treated patients with NSCLC who have wild-type EGFR tumours.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments